Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | S100A9 | P06702 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23358220 | 0.80 | PTGDR2 (0.37) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL1700090 | 0.78 | CA2 (0.48) | CA1CA2CA9GAA | |
| SCHEMBL21633471 | 0.77 | ALDH1A1 (0.38) | GABRA2ALDH1A1LMNACA1CA2 | |
| SCHEMBL21633518 | 0.77 | ALDH1A1 (0.37) | ALDH1A1LMNACA1CA2CA9 | |
| SCHEMBL1370049 | 0.71 | PSEN1 (0.41) | GABRA2CA1CA2CA9 | |
| SCHEMBL2636788 | 0.69 | SMN1; SMN2 (0.39) | ALDH1A1FEN1LMNAGAAMAPT | |
| SCHEMBL15052712 | 0.69 | S100A9 (0.39) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL7681305 | 0.68 | ALDH1A1 (0.58) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL29529396 | 0.68 | TRPV4 (0.47) | FEN1HRH4ABL1NR1H2NR1H3 | |
| SCHEMBL15794097 | 0.68 | IDO1 (0.40) | GABRA2CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162878-B2 | BRD4 inhibitor as well as a preparative method and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2024-12-10 | — | — | US | disclosed |
| CN-110776508-B | BRD4 inhibitor and preparation method and application thereof | 海创药业股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3831828-A1 | BRD4 INHIBITOR, PREPARATION METHOD AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-20210147419-A1 | BRD4 inhibitor as well as a preparative method and use thereof | HINOVA PHARMACEUTICALS INC. (CN) | 2021-05-20 | — | — | US | disclosed |
| CN-110776508-A | BRD4 inhibitor and preparation method and application thereof | 成都海创药业有限公司 | 2020-02-11 | — | — | CN | disclosed |
| WO-2020020308-A1 | BRD4 INHIBITOR, PREPARATION METHOD AND USE THEREOF | 成都海创药业有限公司 | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147419-A1 | BRD4 inhibitor as well as a preparative method and use thereof | BICRA, BRD4, BRDT | GABRA2 1023/4885ALDH1A1 4539/4885FEN1 3639/4885 |
| US-12162878-B2 | BRD4 inhibitor as well as a preparative method and use thereof | BICRA, BRD4, BRDT | GABRA2 1023/4885ALDH1A1 4539/4885FEN1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.